Does the media refer more to DRIO or KRMD?

In the previous week, DarioHealth had 1 more articles in the media than KORU Medical Systems. MarketBeat recorded 4 mentions for DarioHealth and 3 mentions for KORU Medical Systems. DarioHealth's average media sentiment score of 0.79 beat KORU Medical Systems' score of 0.62 indicating that DarioHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DarioHealth 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KORU Medical Systems 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DRIO or FOCL more profitable?

FocalTherics has a net margin of -41.47% compared to DarioHealth's net margin of -192.23%. DarioHealth's return on equity of -60.52% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% FocalTherics -41.47% -137.61% -40.62%

Which has higher earnings & valuation, DRIO or INFU?

InfuSystem has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DarioHealth $21.19M 2.25 -$41.71M -$8.88 N/A InfuSystem $142.40M 1.30 $870K $0.38 24.18

Is DRIO or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to DarioHealth's net margin of -192.23%. InfuSystem's return on equity of 2.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% InfuSystem 1.12% 2.78% 1.41%

Which has higher valuation & earnings, PDEX or DRIO?

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $74.64M 2.49 $8.98M $3.62 16.09 DarioHealth $21.19M 2.25 -$41.71M -$8.88 N/A

Is PDEX or DRIO more profitable?

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% DarioHealth -192.23% -60.52% -37.08%

Does the media prefer PDEX or DRIO?

In the previous week, Pro-Dex and Pro-Dex both had 4 articles in the media. Pro-Dex's average media sentiment score of 1.46 beat DarioHealth's score of 0.79 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DarioHealth 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DarioHealth (DRIO) Competitors

$6.53 -0.17 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$6.70 +0.17 (+2.53%)

As of 07:40 PM Eastern

Compare

DRIO vs. KRMD, FOCL, LUCD, INFU, and PDEX

Should you buy DarioHealth stock or one of its competitors? MarketBeat compares DarioHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DarioHealth include KORU Medical Systems (KRMD), FocalTherics (FOCL), Lucid Diagnostics (LUCD), InfuSystem (INFU), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.

How does DarioHealth compare to KORU Medical Systems?

DarioHealth (NASDAQ:DRIO) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

KORU Medical Systems has higher revenue and earnings than DarioHealth. KORU Medical Systems is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$21.19M	2.25	-$41.71M	-$8.88	N/A
KORU Medical Systems	$41.13M	4.63	-$2.64M	-$0.05	N/A

DarioHealth has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

KORU Medical Systems has a net margin of -5.27% compared to DarioHealth's net margin of -192.23%. KORU Medical Systems' return on equity of -13.61% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

In the previous week, DarioHealth had 1 more articles in the media than KORU Medical Systems. MarketBeat recorded 4 mentions for DarioHealth and 3 mentions for KORU Medical Systems. DarioHealth's average media sentiment score of 0.79 beat KORU Medical Systems' score of 0.62 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KORU Medical Systems	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DarioHealth presently has a consensus price target of $10.50, suggesting a potential upside of 60.80%. KORU Medical Systems has a consensus price target of $7.25, suggesting a potential upside of 74.70%. Given KORU Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe KORU Medical Systems is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

KORU Medical Systems beats DarioHealth on 12 of the 16 factors compared between the two stocks.

How does DarioHealth compare to FocalTherics?

DarioHealth (NASDAQ:DRIO) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DarioHealth currently has a consensus target price of $10.50, suggesting a potential upside of 60.80%. FocalTherics has a consensus target price of $6.00, suggesting a potential upside of 10.91%. Given DarioHealth's higher probable upside, equities research analysts plainly believe DarioHealth is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DarioHealth has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

FocalTherics has higher revenue and earnings than DarioHealth. FocalTherics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$21.19M	2.25	-$41.71M	-$8.88	N/A
FocalTherics	$70.53M	2.87	-$29.25M	-$0.81	N/A

In the previous week, DarioHealth had 3 more articles in the media than FocalTherics. MarketBeat recorded 4 mentions for DarioHealth and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat DarioHealth's score of 0.79 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
DarioHealth	Positive
FocalTherics	Very Positive

FocalTherics has a net margin of -41.47% compared to DarioHealth's net margin of -192.23%. DarioHealth's return on equity of -60.52% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
FocalTherics	-41.47%	-137.61%	-40.62%

Summary

FocalTherics beats DarioHealth on 8 of the 14 factors compared between the two stocks.

How does DarioHealth compare to Lucid Diagnostics?

DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DarioHealth has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$21.19M	2.25	-$41.71M	-$8.88	N/A
Lucid Diagnostics	$4.71M	43.11	-$58.01M	-$0.47	N/A

In the previous week, DarioHealth had 3 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for DarioHealth and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.87 beat DarioHealth's score of 0.79 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
DarioHealth	Positive
Lucid Diagnostics	Very Positive

DarioHealth has a net margin of -192.23% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Lucid Diagnostics	-876.72%	N/A	-116.26%

DarioHealth presently has a consensus price target of $10.50, indicating a potential upside of 60.80%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 318.75%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DarioHealth has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

Lucid Diagnostics beats DarioHealth on 9 of the 16 factors compared between the two stocks.

How does DarioHealth compare to InfuSystem?

DarioHealth (NASDAQ:DRIO) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

DarioHealth has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to DarioHealth's net margin of -192.23%. InfuSystem's return on equity of 2.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
InfuSystem	1.12%	2.78%	1.41%

DarioHealth presently has a consensus target price of $10.50, suggesting a potential upside of 60.80%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 63.22%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$21.19M	2.25	-$41.71M	-$8.88	N/A
InfuSystem	$142.40M	1.30	$870K	$0.38	24.18

In the previous week, DarioHealth had 4 more articles in the media than InfuSystem. MarketBeat recorded 4 mentions for DarioHealth and 0 mentions for InfuSystem. DarioHealth's average media sentiment score of 0.79 beat InfuSystem's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
InfuSystem	Neutral

Summary

InfuSystem beats DarioHealth on 13 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

In the previous week, Pro-Dex and Pro-Dex both had 4 articles in the media. Pro-Dex's average media sentiment score of 1.46 beat DarioHealth's score of 0.79 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pro-Dex presently has a consensus target price of $70.00, suggesting a potential upside of 20.15%. DarioHealth has a consensus target price of $10.50, suggesting a potential upside of 60.80%. Given DarioHealth's higher probable upside, analysts clearly believe DarioHealth is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
DarioHealth	-192.23%	-60.52%	-37.08%

Pro-Dex has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$74.64M	2.49	$8.98M	$3.62	16.09
DarioHealth	$21.19M	2.25	-$41.71M	-$8.88	N/A

Summary

Pro-Dex beats DarioHealth on 12 of the 15 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRIO vs. The Competition

Export

Metric	DarioHealth	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$47.75M	$7.29B	$6.72B	$12.54B
Dividend Yield	N/A	1.32%	2.68%	8.00%
P/E Ratio	-0.74	50.48	27.04	24.40
Price / Sales	2.25	75.22	584.12	117.53
Price / Cash	N/A	26.85	29.22	49.36
Price / Book	0.65	7.07	10.81	6.34
Net Income	-$41.71M	$162.30M	$3.59B	$331.02M
7 Day Performance	-7.77%	-2.46%	-2.24%	-1.09%
1 Month Performance	-7.51%	-1.38%	3.12%	-0.49%
1 Year Performance	-53.36%	3.26%	26.30%	19.90%

DarioHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRIO DarioHealth	2.9617 of 5 stars	$6.53 -2.5%	$10.50 +60.8%	-53.4%	$47.75M	$21.19M	N/A	200
KRMD KORU Medical Systems	4.2704 of 5 stars	$4.48 -2.4%	$7.25 +61.8%	+21.6%	$205.31M	$41.13M	N/A	80
FOCL FocalTherics	2.2397 of 5 stars	$5.41 +1.1%	$6.00 +10.9%	N/A	$202.77M	$70.53M	N/A	230
LUCD Lucid Diagnostics	4.1663 of 5 stars	$0.98 -5.1%	$4.19 +328.6%	-13.1%	$198.40M	$4.71M	N/A	70	Positive News
INFU InfuSystem	3.3717 of 5 stars	$9.76 +0.7%	$15.00 +53.8%	+60.3%	$196.88M	$142.40M	162.61	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRIO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DarioHealth (DRIO) Competitors

DRIO vs. KRMD, FOCL, LUCD, INFU, and PDEX

How does DarioHealth compare to KORU Medical Systems?

Summary

How does DarioHealth compare to FocalTherics?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Summary

How does DarioHealth compare to InfuSystem?

Summary

How does DarioHealth compare to Pro-Dex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DarioHealth (DRIO) Competitors

DRIO vs. KRMD, FOCL, LUCD, INFU, and PDEX

How does DarioHealth compare to KORU Medical Systems?

Do insiders & institutionals hold more shares of DRIO or KRMD?

Which has higher valuation and earnings, DRIO or KRMD?

Which has more volatility & risk, DRIO or KRMD?

Is DRIO or KRMD more profitable?

Does the media refer more to DRIO or KRMD?

Do analysts rate DRIO or KRMD?

Summary

How does DarioHealth compare to FocalTherics?

Do insiders & institutionals hold more shares of DRIO or FOCL?

Do analysts prefer DRIO or FOCL?

Which has more volatility and risk, DRIO or FOCL?

Which has better earnings and valuation, DRIO or FOCL?

Does the media favor DRIO or FOCL?

Is DRIO or FOCL more profitable?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Do institutionals & insiders believe in DRIO or LUCD?

Which has stronger earnings & valuation, DRIO or LUCD?

Does the media favor DRIO or LUCD?

Is DRIO or LUCD more profitable?

Do analysts prefer DRIO or LUCD?

Which has more volatility & risk, DRIO or LUCD?

Summary

How does DarioHealth compare to InfuSystem?

Which has more risk & volatility, DRIO or INFU?

Do insiders and institutionals hold more shares of DRIO or INFU?

Is DRIO or INFU more profitable?

Do analysts rate DRIO or INFU?

Which has higher earnings & valuation, DRIO or INFU?

Does the media favor DRIO or INFU?

Summary

How does DarioHealth compare to Pro-Dex?

Does the media prefer PDEX or DRIO?

Do institutionals & insiders have more ownership in PDEX or DRIO?

Do analysts rate PDEX or DRIO?

Is PDEX or DRIO more profitable?

Which has more volatility & risk, PDEX or DRIO?

Which has higher valuation & earnings, PDEX or DRIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools